We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ANI Pharmaceuticals Acquires 31 Generic Drug Products from Teva Pharmaceuticals
News

ANI Pharmaceuticals Acquires 31 Generic Drug Products from Teva Pharmaceuticals

ANI Pharmaceuticals Acquires 31 Generic Drug Products from Teva Pharmaceuticals
News

ANI Pharmaceuticals Acquires 31 Generic Drug Products from Teva Pharmaceuticals

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ANI Pharmaceuticals Acquires 31 Generic Drug Products from Teva Pharmaceuticals"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ANI Pharmaceuticals, Inc has announced that it has acquired 31 previously marketed generic drug products from Teva Pharmaceuticals for $12.5 million in cash and a percentage of future gross profits from product sales.

The acquisition includes 20 solid-oral immediate release products, 4 extended release products and 7 liquid products.

ANI will begin work immediately on transferring these products into its manufacturing facilities in anticipation of product launches beginning in the fourth quarter of 2014. All of these products have been previously approved by FDA as abbreviated new drug applications (ANDAs). The total current annual market for these products is $860 million per IMS Health.

Arthur S. Przybyl, President and CEO of ANI Pharmaceuticals, stated, “This acquisition is a significant opportunity for ANI to expand our generic product portfolio beyond our current seven marketed products. When launched, these products will strengthen our business by growing our revenue base and leveraging our manufacturing capabilities. We are excited that this transaction extends the ANI-Teva relationship beyond the existing generic testosterone gel partnership.”

Robert W. Schrepfer, VP of New Business Development, commented, “This transaction demonstrates ANI’s commitment to diversify our marketed product portfolio and supplement our internal product development efforts through a business development plan that includes partnerships, acquisitions and in-licensing.”

Advertisement